Complement C3 inhibition in severe COVID-19 using compstatin AMY-101 (2022)
Skendros, Panagiotis; Germanidis, Georgios; Mastellos, Dimitrios C.; Antoniadou, Christina; Gavriilidis, Efstratios; Kalopitas, Georgios; Samakidou, Anna; Liontos, Angelos; Chrysanthopoulou, Akrivi; Calado, Rodrigo Tocantins 
; Lambris, John D.
Source: Science Advances. Unidade: FMRP
Subjects: IMUNOPROTEÍNAS, COVID-19, INIBIDORES QUÍMICOS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SKENDROS, Panagiotis et al. Complement C3 inhibition in severe COVID-19 using compstatin AMY-101. Science Advances, v. 8, n. 33, p. 1-12, 2022Tradução . . Disponível em: https://doi.org/10.1126/sciadv.abo2341. Acesso em: 30 abr. 2026.APA
Skendros, P., Germanidis, G., Mastellos, D. C., Antoniadou, C., Gavriilidis, E., Kalopitas, G., et al. (2022). Complement C3 inhibition in severe COVID-19 using compstatin AMY-101. Science Advances, 8( 33), 1-12. doi:10.1126/sciadv.abo2341NLM
Skendros P, Germanidis G, Mastellos DC, Antoniadou C, Gavriilidis E, Kalopitas G, Samakidou A, Liontos A, Chrysanthopoulou A, Calado RT, Lambris JD. Complement C3 inhibition in severe COVID-19 using compstatin AMY-101 [Internet]. Science Advances. 2022 ; 8( 33): 1-12.[citado 2026 abr. 30 ] Available from: https://doi.org/10.1126/sciadv.abo2341Vancouver
Skendros P, Germanidis G, Mastellos DC, Antoniadou C, Gavriilidis E, Kalopitas G, Samakidou A, Liontos A, Chrysanthopoulou A, Calado RT, Lambris JD. Complement C3 inhibition in severe COVID-19 using compstatin AMY-101 [Internet]. Science Advances. 2022 ; 8( 33): 1-12.[citado 2026 abr. 30 ] Available from: https://doi.org/10.1126/sciadv.abo2341
